Intervention for oxaliplatin-induced hypersensitivity in China: a cross-sectional internet-based survey*

Author:

Li Min1,Li Wei1,Wang Yue2,Shangguan Xiaofang3,Huang Rui3,Liu Dong1,Zhang Chengliang1

Affiliation:

1. Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China

2. Statistical Department, Tongji Hospital Affiliated with Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China

3. School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China

Abstract

Abstract Objective This cross-sectional study aimed at investigating the intervention status and the influence of oncologists on oxaliplatin-induced hypersensitivity reactions (OIHR). Methods Snowball sampling was used to send questionnaires to oncologists in various provinces and cities in China, via the internet, to collect data on their socio-demographic characteristics, the occurrence of OIHR, and the current status of interventions. One-way ANOVA and T-test of geographic samples were used to explore the relationship between the incidence of OIHR and intervention measures. Results A total of 401 valid questionnaires were collected, most respondents were 30-40 years old, and most oncologists had 5 years of working experience. The proportions of glucocorticoid and H1 receptor antagonist use for OIHR prevention were 67.83% and 38.65%, respectively. The proportion of oncologists with longer working years and higher professional titles who used glucocorticoids for OIHR prevention was higher, and the observed OIHR incidence was lower. Pretreatment with glucocorticoids may be an effective preventive measure and can reduce the incidence of the OXA allergic reactions (P < 0.05). Conclusion The risk awareness of junior oncologists to OIHR prevention should be strengthened, and clinical efficacy evaluation of glucocorticoids in OIHR prevention should be further promoted.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Reference17 articles.

1. Type II hypersensitivity reactions after oxaliplatin rechallenge can be life threatening.;Vyskocil;Int Immunopharmacol,,2019

2. Hypersensitivity to oxaliplatin: clinical features and risk factors.;Parel;BMC Pharmacol Toxicol,,2014

3. Acute oxaliplatin-induced hemolytic anemia, thrombocytopenia, and renal failure: case report and a literature review.;Phull;Clin Colorectal Cancer,,2017

4. Oxaliplatin: detection and management of hypersensitivity Reactions.;Rogers;Clin J Oncol Nurs,,2019

5. Desensitization to oxaliplatin with two stages of premedication in a patient with metastatic rectal cancer.;Nozawa;Clin Ther,,2008

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3